IE
RNTX

Israel Englander’s Rein Therapeutics RNTX Stock Holding History

Israel Englander’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-600
Closed -$2K – 7155
2022
Q3 		$2K Buy
+600
New +$2.53K ﹤0.01% 6930
2022
Q1 		– Sell
-1,577
Closed -$18K – 7608
2021
Q4 		$18K Sell
1,577
-1,279
-45% -$19.8K ﹤0.01% 6612
2021
Q3 		$58K Sell
2,856
-236
-8% -$5.17K ﹤0.01% 6553
2021
Q2 		$77K Buy
+3,092
New +$77.1K ﹤0.01% 6302
2020
Q4 		– Sell
-744
Closed -$19 – 5659
2020
Q3 		$19 Buy
+744
New +$17.5K ﹤0.01% 4354
2019
Q1 		– Sell
-2,177
Closed -$37K – 4395
2018
Q4 		$37K Sell
2,177
-2,008
-48% -$80.7K ﹤0.01% 3640
2018
Q3 		$230K Sell
4,185
-1,998
-32% -$134K ﹤0.01% 3586
2018
Q2 		$670K Buy
6,183
+5,254
+566% +$595K ﹤0.01% 3033
2018
Q1 		$151K Buy
+929
New +$166K ﹤0.01% 3426
2017
Q4 		– Sell
-1,847
Closed -$494K – 4132
2017
Q3 		$494K Sell
1,847
-4,257
-70% -$1.07M ﹤0.01% 2849
2017
Q2 		$1.36M Buy
+6,104
New +$1.34M ﹤0.01% 2299

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Israel Englander's RNTX Position: Q4 2022 in Review

Israel Englander sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 600 shares — an estimated $2K sold.

Israel Englander first reported a position in RNTX in Q2 2017 and held it in 11 quarters. The position peaked at $1.36M in Q2 2017. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

  • Israel Englander reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Israel Englander sold 600 Rein Therapeutics shares in Q4 2022, an estimated $2K.
  • Israel Englander first reported a position in Rein Therapeutics in Q2 2017 and held it in 11 quarters.
  • Israel Englander's Rein Therapeutics position peaked at $1.36M in Q2 2017.
  • 19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.